JP2024520727A5 - - Google Patents

Info

Publication number
JP2024520727A5
JP2024520727A5 JP2023574780A JP2023574780A JP2024520727A5 JP 2024520727 A5 JP2024520727 A5 JP 2024520727A5 JP 2023574780 A JP2023574780 A JP 2023574780A JP 2023574780 A JP2023574780 A JP 2023574780A JP 2024520727 A5 JP2024520727 A5 JP 2024520727A5
Authority
JP
Japan
Prior art keywords
bcma
domain
trispecific protein
approximately
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023574780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031917 external-priority patent/WO2022256499A2/en
Publication of JP2024520727A publication Critical patent/JP2024520727A/ja
Publication of JP2024520727A5 publication Critical patent/JP2024520727A5/ja
Withdrawn legal-status Critical Current

Links

JP2023574780A 2021-06-03 2022-06-02 Bcma標的化三重特異性タンパク質およびその使用 Withdrawn JP2024520727A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163196595P 2021-06-03 2021-06-03
US63/196,595 2021-06-03
US202163288124P 2021-12-10 2021-12-10
US63/288,124 2021-12-10
PCT/US2022/031917 WO2022256499A2 (en) 2021-06-03 2022-06-02 Bcma targeting trispecific proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2024520727A JP2024520727A (ja) 2024-05-24
JP2024520727A5 true JP2024520727A5 (cg-RX-API-DMAC7.html) 2025-06-10

Family

ID=84323567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574780A Withdrawn JP2024520727A (ja) 2021-06-03 2022-06-02 Bcma標的化三重特異性タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20240254250A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347636A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520727A (cg-RX-API-DMAC7.html)
AU (1) AU2022286960A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220878A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022256499A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315737A (en) * 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) * 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2024523003A5 (cg-RX-API-DMAC7.html)
JP2024532374A5 (cg-RX-API-DMAC7.html)
Wilson et al. Enhancement of tumor radiation response by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid
JP2022509358A5 (cg-RX-API-DMAC7.html)
JP2008503476A5 (cg-RX-API-DMAC7.html)
US20050244407A1 (en) Therapeutic synergy of anti-cancer compounds
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2004512262A5 (cg-RX-API-DMAC7.html)
JP2013520442A5 (cg-RX-API-DMAC7.html)
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
JP2006513184A5 (cg-RX-API-DMAC7.html)
JP7518816B2 (ja) 治療抵抗性がんの予防又は治療用の医薬組成物
JP2021518394A5 (cg-RX-API-DMAC7.html)
JP2020523354A5 (cg-RX-API-DMAC7.html)
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
JP2022523045A5 (cg-RX-API-DMAC7.html)
JP2022523530A5 (cg-RX-API-DMAC7.html)
WO2025061121A1 (zh) 治疗非霍奇金淋巴瘤的药物、药物组合及其用途
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2004537500A5 (cg-RX-API-DMAC7.html)
MX2024014994A (es) Macrociclos de indazol y su uso
JP2024016209A5 (cg-RX-API-DMAC7.html)
JP2023524359A5 (cg-RX-API-DMAC7.html)
JP2003528919A5 (cg-RX-API-DMAC7.html)